Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sargent

Showing results (81-90 of 514) with videos related to

Pageof 52
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
All-comers versus enrichment design strategy in phase II trialsSumithra J Mandrekar, Daniel J Sargent
Clinical Investigation|March 6, 2012
Design of clinical trials for biomarker research in oncologySumithra J Mandrekar, Daniel J Sargent
Statistics in Medicine|June 15, 1996
Robust Bayesian approaches for clinical trial monitoringB P Carlin, D J Sargent
Headache|March 1, 1984
Menstrual migraine headache: results of a controlled, experimental, outcome study of non-drug treatmentsP Solbach, J Sargent, L Coyne
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Pick the winner designs in phase II cancer clinical trialsSumithra J Mandrekar, Daniel J Sargent
Journal of Biopharmaceutical Statistics|April 23, 2009
Clinical trial designs for predictive biomarker validation: one size does not fit allSumithra J Mandrekar, Daniel J Sargent
European Journal of Cancer (Oxford, England : 1990)|December 9, 2008
Optimising the design of phase II oncology trials: the importance of randomisationMark J Ratain, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challengesSumithra J Mandrekar, Daniel J Sargent
Journal of the National Cancer Institute|February 7, 2016
One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancerHoward S Hochster, Daniel J Sargent
Proceedings of the National Academy of Sciences of the United States of America|April 21, 2022
Three world wars: Fiscal-monetary consequencesGeorge J Hall, Thomas J Sargent
Pageof 52

Showing results (81-90 of 514) with videos related to

Sort By:
Pageof 52
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
All-comers versus enrichment design strategy in phase II trialsSumithra J Mandrekar, Daniel J Sargent
Clinical Investigation|March 6, 2012
Design of clinical trials for biomarker research in oncologySumithra J Mandrekar, Daniel J Sargent
Statistics in Medicine|June 15, 1996
Robust Bayesian approaches for clinical trial monitoringB P Carlin, D J Sargent
Headache|March 1, 1984
Menstrual migraine headache: results of a controlled, experimental, outcome study of non-drug treatmentsP Solbach, J Sargent, L Coyne
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Pick the winner designs in phase II cancer clinical trialsSumithra J Mandrekar, Daniel J Sargent
Journal of Biopharmaceutical Statistics|April 23, 2009
Clinical trial designs for predictive biomarker validation: one size does not fit allSumithra J Mandrekar, Daniel J Sargent
European Journal of Cancer (Oxford, England : 1990)|December 9, 2008
Optimising the design of phase II oncology trials: the importance of randomisationMark J Ratain, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2009
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challengesSumithra J Mandrekar, Daniel J Sargent
Journal of the National Cancer Institute|February 7, 2016
One good DNA-damage deserves another: Oxaliplatin in MSI-high colon cancerHoward S Hochster, Daniel J Sargent
Proceedings of the National Academy of Sciences of the United States of America|April 21, 2022
Three world wars: Fiscal-monetary consequencesGeorge J Hall, Thomas J Sargent
Pageof 52